Apixaban and Tagrisso drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Apixaban (apixaban) and Tagrisso (osimertinib mesylate). Common drug interactions include cerebrovascular accident among females and metastases to central nervous system among males.

The phase IV clinical study analyzes what interactions people have when they take Apixaban and Tagrisso. It is created by eHealthMe based on reports of 19 people who take the same drugs from the FDA, and is updated regularly.

What is Apixaban?

Apixaban has active ingredients of apixaban. It is often used in blood clots. eHealthMe is studying from 60,351 Apixaban users. Check the latest studies of Apixaban.

What is Tagrisso?

Tagrisso has active ingredients of osimertinib mesylate. eHealthMe is studying from 19,890 Tagrisso users. Check the latest studies of Tagrisso.

On Jul, 09, 2026

19 people who take Apixaban and Tagrisso together, and have interactions are studied.

Apixaban and Tagrisso drug interactions.

What are the common drug interactions of Apixaban and Tagrisso, by gender? *:

female:

Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
Cardiac failure
Pneumonia
Pulmonary alveolar haemorrhage (acute bleeding)
Arterial haemorrhage
Asthenia (weakness)
Cerebral artery thrombosis (clot formation in brain blood vessels)
Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)
Platelet count decreased
Respiratory failure (inadequate gas exchange by the respiratory system)

male:

Metastases to central nervous system (cancer spreads to central nervous system)
Agitation (state of anxiety or nervous excitement)
Cognitive disorder (mental health disorders affects learning, memory, perception, and problem solving)
Delirium (wild excitement)
Fatigue (feeling of tiredness)
Thought blocking (a sudden inability to finish a thought)
Malignant neoplasm progression (cancer tumour came back)
Cerebral disorder (brain disease)
Pulmonary thrombosis (scarring in the lungs)
Thrombosis (formation of a blood clot inside a blood vessel)

What are the common drug interactions of Apixaban and Tagrisso, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Back pain

40-49:

Lung adenocarcinoma metastatic (a form of non-small cell lung cancer spreads to other part)

50-59:

Embolic stroke (stroke due to obstruction due to an embolus)

60+:

Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
Cardiac failure
Thrombocytopenia (decrease of platelets in blood)
White blood cell count increased
Cerebral infarction (less blood supply to brain resulting tissue damage)
Decreased interest
Fatigue (feeling of tiredness)
Malignant neoplasm progression (cancer tumour came back)
Otitis media (inflammation of the middle ear)
Pneumonia

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 8 people, 42.11%
Pulmonary Embolism (blockage of the main artery of the lung): 2 people, 10.53%
Non-Small Cell Lung Cancer Metastatic (type of epithelial lung cancer spreads to other parts): 2 people, 10.53%
Embolism Venous (embolus may pass into the arterial system): 2 people, 10.53%
Skin Cancer: 1 person, 5.26%
Non-Small Cell Lung Cancer Stage Iv: 1 person, 5.26%
Neoplasm Malignant (cancer tumour): 1 person, 5.26%
Metastases To Bone (cancer spreads to bone): 1 person, 5.26%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Apixaban and Tagrisso?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously